Ad
SILO Quote Trading Chart Silo Pharma Inc.
home / stock / silo / silo quote
Quote | Silo Pharma Inc. (NASDAQ:SILO)
| Last: | $0.922 |
|---|---|
| Change Percent: | -1.1% |
| Open: | $0.96 |
| Close: | $0.922 |
| High: | $0.96 |
| Low: | $0.889 |
| Volume: | 89,716 |
| Last Trade Date Time: | 12/12/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
SILO Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $0.922 | $0.96 | $0.922 | $0.96 | $0.889 | 89,716 | 12-12-2024 |
| $0.9496 | $0.94 | $0.9496 | $0.98 | $0.9211 | 74,093 | 12-11-2024 |
| $0.94 | $0.91 | $0.94 | $0.95 | $0.9031 | 21,253 | 12-10-2024 |
| $0.903 | $0.928 | $0.903 | $0.96 | $0.9 | 214,821 | 12-09-2024 |
| $0.924 | $0.92 | $0.924 | $0.95 | $0.9 | 161,357 | 12-06-2024 |
| $0.93 | $0.98 | $0.93 | $0.98 | $0.911 | 124,047 | 12-05-2024 |
| $0.969 | $1.02 | $0.969 | $1.02 | $0.9601 | 144,698 | 12-04-2024 |
| $1 | $0.95 | $1 | $1.05 | $0.95 | 132,551 | 12-03-2024 |
| $1.05 | $0.99 | $1.05 | $1.11 | $0.8599 | 812,973 | 12-02-2024 |
| $1 | $1.03 | $1 | $1.1 | $0.933 | 8,598,610 | 11-29-2024 |
| $0.9 | $0.93 | $0.9 | $0.943 | $0.8506 | 87,263 | 11-28-2024 |
| $0.9 | $0.93 | $0.9 | $0.943 | $0.8506 | 87,263 | 11-27-2024 |
| $0.88 | $0.8449 | $0.88 | $0.9 | $0.8449 | 83,912 | 11-26-2024 |
| $0.871 | $0.86 | $0.871 | $0.89 | $0.77 | 109,432 | 11-25-2024 |
| $0.86 | $0.91 | $0.86 | $0.9878 | $0.83 | 141,926 | 11-22-2024 |
| $0.91 | $0.93 | $0.91 | $0.95 | $0.91 | 101,938 | 11-21-2024 |
| $0.9451 | $0.97 | $0.9451 | $1.01 | $0.9302 | 128,900 | 11-20-2024 |
| $0.9699 | $1 | $0.9699 | $1.04 | $0.96 | 185,973 | 11-19-2024 |
| $0.99 | $1.08 | $0.99 | $1.1 | $0.98 | 830,166 | 11-18-2024 |
| $1.13 | $1.14 | $1.13 | $1.2116 | $1.1 | 221,630 | 11-15-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
Silo Pharma (NASDAQ: SILO) has entered into a collaboration with Kymanox to develop a subcutaneous insertion device for SP-26, its ketamine-loaded implant designed to treat fibromyalgia and chronic pain. The partnership will begin with proof-of-concept design, followed by prototype and feasibili...
-
Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on dev...
-
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing SPC-15 as an intranasal treatment for PTSD SARASOTA, FL, Nov. 18, 2024 (GLOBE NEWSWIRE...